Solid first-quarter earnings, positive phase III data on Soliris (eculizumab) successor ALXN-1210, and rosy revenue guidance sent shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) climbing Thursday as the company pushed ahead with efforts to rebuild its pipeline. It reported earnings of $1.68 per share, beating analyst expectations of $1.50.